Company intelligence / Profile preview

Tenet Shareholder Committee

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Tenet Medicines was a development-stage biotechnology company focused on advancing therapies for autoimmune and inflammatory diseases. The company's lead asset, TNT001 (now LY3845087), is a potent, clinical-stage monoclonal antibody targeting CD19, designed to deplete B cells for the treatment of systemic lupus erythematosus and other B-cell mediated conditions. Tenet was founded by industry veterans with the goal of optimizing B-cell depletion strategies to provide better outcomes for patients with refractory autoimmune disorders. In April 2024, the company was acquired by Eli Lilly and Company to bolster Lilly's immunology pipeline.

Therapeutic areas: Immunology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Tenet Shareholder Committee.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tenet Shareholder Committee.

Explore the full profile